Sens.AI is a software solution designed to segment and calculate the volume of the biggest homogeneous pathological lesion, dedicated to low and high-grade gliomas (LGG and HGG) within the input MRI scan of human brain, by using T2-FLAIR 3D MRI sequence.
Product specifications Information source: Vendor
Last updated: July 22, 2020
General
Product name Sens.ai
Company Future Processing
Subspeciality Neuro
Modality MR
Disease targeted low and high grade glioblastoma
Key-features lesion segmentation and volume calculation
Suggested use
Data characteristics
Population all adults with glioblastoma
Input FLAIR 3D MR sequence
Input format DICOM
Output lesion segmentation, volume calculation
Output format DICOM
Technology
Integration Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 3 - 10 seconds
Certification
CE Certified, Class IIa
FDA No or not yet
Market presence
On market since 03-2020
Distribution channels Eureka Clinical AI
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model
Based on
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers